Odyssey Therapeutics, Inc. ODTX
19.31 USD -2.26 (-10.48%)
Nov 4, 2026, 3:39 PM EST
19.05 Day range 22.36
15.10 52-week range 29.05
- YTD
- +17.60%
- 1 year
- +17.60%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.33 +83.0% upside
Now 19.31
- Target (low)
- 27.00
- Target (mean)
- 35.33
- Target (high)
- 44.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 6
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.93023 | -1.07 – -0.81 | 0.00 | 0.0% | 0 | 0.0% | 3 |
| Next quarter | -1.01 | -1.17 – -0.85 | 0.00 | 0.0% | 0 | 0.0% | 3 |
| Current year | -4.11 | -4.33 – -3.89 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next year | -4.36 | -5.08 – -3.45 | -4.11 | -6.1% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | Initiated | — | Buy |
| Oct 9, 2026 | Raymond James | Initiated | — | Outperform |
| Aug 27, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 18, 2026 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jun 2, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 2, 2026 | TD Cowen | Initiated | — | Buy |
| Jun 2, 2026 | Wedbush | Initiated | — | Outperform |
| Jun 2, 2026 | JP Morgan | Initiated | — | Overweight |
| Jun 2, 2026 | Oppenheimer | Initiated | — | Outperform |